Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis (BAT-SCAN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01887769|
Recruitment Status : Unknown
Verified January 2017 by Didier Saey, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec.
Recruitment status was: Recruiting
First Posted : June 27, 2013
Last Update Posted : January 6, 2017
Rationale: With 1.6 million new cases diagnosed each year and 1.3 million deaths, lung cancer is the leading cancer-related death worldwide and it represents a pressing health issue. Patients with lung cancer are more likely to experience cachexia, a severe debilitating disorder causing fatigue, weight loss, muscle wasting and associated with reduced physical function, increased chemotherapy toxicity and reduced survival. This syndrome occurring in about 80% of advanced cancer patients is the direct cause of death in about 20% of cases. However, despite the importance of cachexia in lung cancer, it has been mainly studied from several assessment methods which do not usually differentiate muscle from other tissues.
Aim: To analyze body composition of patients with lung cancer at diagnosis using computed tomography (CT-Scan) image analysis.
Methods: This is a retrospective study extending over a period of 3 years conducted at the Institut universitaire de cardiologie et de pneumologie de Québec (2009-2012). We listed patients newly diagnosed with lung cancer who had a thoraco-abdominal CT-scan performed in our institution. Following the collection of clinical data from patient records, we used SliceOmatic software to quantify muscle area, visceral fat area and subcutaneous fat area from a single abdominal cross-sectional image at the level of the third lumbar vertebra.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||July 2017|
|Estimated Study Completion Date :||October 2017|
|Lung cancer patient at diagnosis|
- Change of muscle area (cm2/m2) at the level of the third lumbar vertebra [ Time Frame: at the time of the diagnosis of lung cancer and one year following it. ]
- Change of fat area (cm2/m2) at the level of the third lumbar vertebra [ Time Frame: at the time of the diagnosis of lung cancer and one year following it. ]
- days of survival [ Time Frame: From the time of the diagnosis of lung cancer until one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01887769
|Institut universitaire de cardiologie et de pneumologie de Québec||Recruiting|
|Québec, Quebec, Canada, G1V 4G5|
|Contact: Didier Saey, PhD 418-656-8711 ext 2614 firstname.lastname@example.org|
|Principal Investigator: Didier Saey, PhD|
|Principal Investigator:||Didier Saey, PhD||Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|